By Michelle Fay Cortez / The Bulletin
March 19, 2010
One of the most eagerly anticipated studies of a drug for Alzheimer’s disease may not yield results until 2012, two years later than had been forecast.
Johnson & Johnson took over development of the medicine, bapineuzumab, when it bought Elan Corp.’s Alzheimer’s program last year. Patients....